Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model - Seite 3

The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer drug candidate for treating sepsis currently in development.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
[phone]
[e-mail]

Media and Investor Relations (AU)
Andrew Geddes
CityPR
[phone]
[e-mail]

Media and Investor Relations (USA)
Meredith Sosulski, Ph.D.
LifeSci Communications
[phone]
[e-mail]

______________________

¹ ‘R111’ a non-descript placeholder name for present purposes
² https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats- ...

Figures accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d0e5db1f-a085-408c ...
https://www.globenewswire.com/NewsRoom/AttachmentNg/3ae3ac8f-1b6f-4159 ...